Pharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorder.

Pharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorder. Expert Opin Pharmacother. 2018 May 04;:1-20 Authors: Lozupone M, La Montagna M, D'Urso F, Piccininni C, Sardone R, Dibello V, Giannelli G, Solfrizzi V, Greco A, Daniele A, Quaranta N, Seripa D, Bellomo A, Logroscino G, Panza F Abstract INTRODUCTION: Pharmacotherapy for the treatment of depressive disorders in Alzheimer's Disease (AD) represents a clinical challenge. pharmacological options are often attempted after a period of watchful waiting (8-12 weeks). monoaminergic antidepressant drugs have shown only modest or null clinical benefits, maybe because the etiology of depressive symptoms in ad patients is fundamentally different from that of nondemented subjects. Areas covered: The following article looks at the selective serotonin reuptake inhibitor sertraline, which is one of the most frequently studied antidepressant medications in randomized controlled trials (RCTs). It also discusses many other pharmacological approaches that have proven to be inadequate (antipsychotics, acetylcholinesterase inhibitors, anticonvulsants, hormone replacement therapy) and new drug classes (mainly affecting glutamate transmission) that are being studied for treating depression in AD. It also gives discussion to the phase II RCT on the alternative drug S47445 and the potential effect on cognition of the multimodal antidepressant vortioxet...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Related Links:

Background: Bright light treatment is a therapeutic intervention mainly used to treat sleep and circadian disturbances in Alzheimer ’s disease (AD) patients. Recently, a handful of studies also focused on the effect on cognition and behavior. Conflicting findings are reported in the literature, and no definite conclusions have been drawn about its specific therapeutic effect.Summary: The aim of this review is to provide a critical evaluation of available evidence in this field, highlighting the specific characteristics of effective bright light treatment. Eligible studies were required to assess at least one of the f...
Source: Dementia and Geriatric Cognitive Disorders - Category: Geriatrics Source Type: research
Authors: Cuenca L, Gil-Martinez AL, Cano-Fernandez L, Sanchez-Rodrigo C, Estrada C, Fernandez-Villalba E, Herrero MT Abstract After Alzheimer's disease, Parkinson's disease (PD) is the second most prevalent and incidental neurodegenerative disorder, affecting more than 2% of the population older than 65 years old. Since it was first described 200 years ago by Dr James Parkinson, great steps have been made in the understanding of the pathology. However, the cause(s) that initiates and perpetuates the neurodegenerative process is (are) still not clear. Thus, early diagnosis is not available, nor are there efficient t...
Source: Histology and Histopathology - Category: Cytology Tags: Histol Histopathol Source Type: research
Authors: Mitolo M, Tonon C, La Morgia C, Testa C, Carelli V, Lodi R Abstract BACKGROUND: Bright light treatment is a therapeutic intervention mainly used to treat sleep and circadian disturbances in Alzheimer's disease (AD) patients. Recently, a handful of studies also focused on the effect on cognition and behavior. Conflicting findings are reported in the literature, and no definite conclusions have been drawn about its specific therapeutic effect. SUMMARY: The aim of this review is to provide a critical evaluation of available evidence in this field, highlighting the specific characteristics of effective bri...
Source: Dementia and Geriatric Cognitive Disorders - Category: Psychiatry Tags: Dement Geriatr Cogn Disord Source Type: research
This article cuts across a broad spectrum of diseases, but is focused on hormones, estrogen and something called the timing hypothesis.This proposition, that estrogen ’s effects on our minds and our bodies may depend heavily upon when we first start taking it, is a controversial and very big idea. It has a working nickname: “the timing hypothesis.”There are some very interesting hypotheses about the health of the brain and Alzheimer's in the article.If the timing hypothesis proves right and estrogen really does protect brains and hearts as long as we start it "at the right time", the calculation...
Source: Alzheimer's Reading Room, The - Category: Neurology Tags: Alzheimer's disease estrogen facts about estrogen health life news women Source Type: blogs
CONCLUSION: We show prospectively that the caregiving experience impacts feelings of relief, and that feeling relieved facilitates postbereavement adjustment by lessening symptoms of complicated grief. PMID: 30503704 [PubMed - as supplied by publisher]
Source: The American Journal of Geriatric Psychiatry - Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research
This study examined the link between depression/anxiety/PTSD and dementia by evaluating the prevalence of these disorders in people with dementia, relative to their healthy peers. Existing meta-analyses have examined the prevalence of clinically-significant depression and anxiety in Alzheimer ’s disease (AD), and depression in frontotemporal dementia (FTD), but have not considered vascular dementia (VaD), dementia with Lewy bodies (DLB), PTSD, or anxiety in FTD. The current meta-analysis compared the prevalence of clinically-significant depression, anxiety and PTSD in the four most com mon types of dementia (AD, VaD,...
Source: Neuropsychology Review - Category: Neuroscience Source Type: research
CONCLUSIONS: There were subgroup differences in low-value care. Interventions may target these subgroups to reduce low-value care. PMID: 30521375 [PubMed - as supplied by publisher]
Source: Aging and Mental Health - Category: Geriatrics Authors: Tags: Aging Ment Health Source Type: research
CONCLUSION: Caregiver profiles are valuable predictors for service use: this knowledge can aid professionals in ensuring optimal access to services, which is important for maintaining independence at home. In addition, the use of supportive and less intrusive, non-personal services in the early stages of dementia is to be advised. PMID: 30518244 [PubMed - as supplied by publisher]
Source: Aging and Mental Health - Category: Geriatrics Authors: Tags: Aging Ment Health Source Type: research
ConclusionsPCA is characterized by preserved to heightened connectivity in the SN and DMN despite decreased visuospatial network connectivity. The spatial similarity of medial and lateral pulvinar connectivity changes to those seen in the SN and DMN suggests a role for the pulvinar in intrinsic connectivity network changes in PCA.
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
After my diagnosis, I silently held out hope that it had all been a big mistake.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Alzheimer's Disease Drugs (Pharmaceuticals) Memory Suicides and Suicide Attempts Source Type: news
More News: Alzheimer's | Depression | Drugs & Pharmacology | Hormone Replacement Therapy | Hormones | Sertraline | Study | Zoloft